Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2023-10-02

Clinical Trial Update: A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes [Phase 2]

View source ↗

Summary

Phase 2 study evaluating rucaparib in participants with solid tumors and deleterious HRR gene mutations; study terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Rucaparib (rucaparib)

Snippet

Sponsor: pharmaand GmbH | Conditions: Solid Tumor | Phase 2 | Status: TERMINATED | Results posted: 2023-10-02